Dr. Theodore D. Tjossem, chief of NICHD’s Mental Retardation and Developmental Disabilities Branch, recently received the Career Research Scientist Award from the American Academy on Mental Retardation in Philadelphia. The award cited Tjossem’s outstanding research contributions to the field of mental retardation.

Ex-Assistant Surgeon General, Dies of Cancer

Dr. Robert S. Gordon Jr., 59, Special Assistant to the Director of the National Institutes of Health and former Assistant Surgeon General of the U.S. Public Health Service, died of esophageal cancer on Friday, Aug. 2, at his home in Kensington, Md.

Dr. Gordon was born in New York City on Mar. 26, 1926.

Dr. Gordon, who also served as Acting Special Assistant to the NIH Director for Research Related to Disease Prevention, received his bachelor’s degree from Harvard College (1947) summa cum laude, and his M.D. degree from Harvard Medical School (1949) magna cum laude. In 1976, he earned a master’s degree in epidemiology from The Johns Hopkins School of Hygiene and Public Health.

Immediately after an internship and residency in internal medicine at Columbia-Presbyterian Hospital, New York City, Dr. Gordon joined NIH in 1953 as a clinical associate in the National Heart Institute (now the National Heart, Lung, and Blood Institute).

During this time he devised methods for measuring non-esterified fatty acids in plasma (which with his particular sense of humor, he wanted to call “plasma soap” but no journal editor would agree to this proposal). He investigated their turnover and showed that under some circumstances they served as the major source of energy for many organs including the heart.

For this work he received the Stouffer Award in 1972.

He then turned his attention to a curious kind of edema which had no known cause. He showed that some of these cases were due to an abnormal loss of protein from the bowel, and devised a test for the diagnosis of this condition.

NIH Has Authority and the Will to Assure Humane Treatment of Animals in Research

But Ultimate Solution Should Be EducativE, Not Regulative, Dr. Charles McCarthy Thinks

Biomedical research using animals has been prominent in the news lately, most immediately at NIH because of a recent 4-day sit-in by an animal rights group.

Because many NIH employees may not be familiar with NIH policies on experiments in which animals are used, Record Editor Herschel Cobb interviewed Dr. Charles McCarthy, director of the Office for Protection Against Research Risks, to get an overview of NIH’s role in the care and use of animals both in its own laboratories and under projects it funds at other biomedical institutions. Highlights from the interview follow:

Q. Why is it so important that we have animal research? I understand that biomedical science is based largely on the assumption that the results from animal experiments can be transferred in most cases to human beings to explain or heal human diseases. Is that true and what is the evidence for it?

A. Yes, it certainly is true. As a matter of fact, I think the overwhelming majority of significant advances in biomedical science that have been made in the last 50 years have involved prior research with animals. And I think one of the things that may not be well understood is that biomedical research not only benefits human beings—I think everybody knows that—but it also benefits animals. And, therefore, the health of animals is greatly enhanced by this research though that may not be the primary purpose.

Q. Many people ask why can’t you substitute computer simulations for a lot of these medical experiments? Why can’t you?

A. Well, of course in some cases we can and do, and NIH is putting an enormous amount of effort into finding alternatives to the use of animals. When we use that word “alternatives”, we mean that portions of the research can be carried out by computer or by in vitro processes in the laboratory. But I don’t think anyone at present foresees a time when the effect of a new device, a new drug, a new procedure will not have to be tried—not just on a computer or in the laboratory—but on a living organism.

These organisms are so complex that one cannot ever anticipate all the effects of a new procedure into finding alternatives to the use of animals. When we use that word “alternatives”, we mean that portions of the research can be carried out by computer or by in vitro processes in the laboratory. But I don’t think anyone at present foresees a time when the effect of a new device, a new drug, a new procedure will not have to be tried—not just on a computer or in the laboratory—but on a living organism.
Daycare, Summer Camp Available to NIH Children

The Preschool/School-Age Program, providing group care for children ages 3 to 12, operates at the Ayrlawn Center near NIH. Open 5 days a week, Monday through Friday from 7:30 a.m. to 6 p.m., the program provides full-time care for preschoolers and before and after-school care.

Transportation is provided for children attending Rosemary Hills Primary School, Wyngate, and North Chevy Chase Elementary Schools.

There are full day programs during school holidays and winter and spring vacations.

The Ayrlawn program has a diversified staff of teachers and teacher aides.

Summer Care

POPI, Inc. also provides summer care for preschoolers and school-age children at Ayrlawn.

There are five 2-week sessions during the summer months. Activities include Spanish speaking lessons, sign language, swimming (three times a week) gymnastics, aerobics, drawing, drama, arts and crafts. Field trips are also included. Recently the children visited The Smithsonian Institution’s American History Building.

Further questions on the Ayrlawn program may be directed to Anne Schmitz, 530-5550 – Marilyn Berman □

Women Runners, Non-Runners Needed as Volunteers For Hormone Study

Volunteers are needed for a study on hormonal changes in female long distance runners. Two categories of women will be tested:

- Women running 35 or more miles per week, and
- Women doing little or no exercise.

Women volunteers must be between 18 and 40 years old, be non-smokers, not taking any medications that would affect their hormone levels.

Each subject will come to the lab for two or three sessions. As part of the study, volunteers will receive a maximum EKG treadmill test, body fat determination by both skinfold and hydrostatic weighing methods, and then individual hormone levels determined by taking blood samples.

If you are interested in participating in this study, call Janet Yu-Yahiro, Department of Physiology, Uniformed Services University, at 295-3623 or 295-3511. □

Normal Volunteer Program Wants To Contact Former NIH Volunteers

The Normal Volunteer Program is interested in knowing how many former college student normal volunteers are now, or have been, employed at NIH following their normal volunteer experience as students.

Former volunteers who are now working at NIH and researchers who have had former normal volunteer experience are asked to contact Loretta Coughlin, assistant chief, Normal Volunteer Program, 496-4763. □
New Test Has Screened-Out AIDS Contaminants From Nation’s Blood Supply, Expert Confernees Say

A new test licensed last spring has apparently succeeded in screening out AIDS-related contaminants from the Nation’s blood supply used for transfusions. These blood sample studies were reported on July 31 at a meeting cosponsored by NIH, the Food and Drug Administration, and the Centers for Disease Control.

The blood tests “are doing an extremely good job of screening the general population and are extremely valuable in screening out infectious blood” contaminated with the virus that causes acquired immune deficiency syndrome, according to Dr. Harry M. Meyer, director, Center for Drugs and Biologies, Food and Drug Administration.

The conference spokesmen said they believe that virtually all donors with suspect blood are being identified and their blood eliminated from the system.

The results of the test were based on more than a million units of blood collected from 131 centers in the U.S. from Apr. 22 to June 16, 1985, representing about 70 percent of the blood collected at those centers.

Transfusion-associated AIDS accounted for about 2 percent (202 cases) of the 12,067 AIDS cases reported to the CDC through July 26. Of the overall total, 6,079 cases have been fatal thus far.

The test measures the amount of antibody that the body produces in response to the presence of HTLV-III, the virus that is believed to cause AIDS. The test does not detect the virus itself but a close correlation was found in one study between presence of the antibody and a later discovery of the presence of the virus.

Three variants of the blood test were reported. These are produced by Abbott Laboratories, Electronucleonics and Litton Industries. The tests are derived from one developed last year by Dr. Robert Gallo’s team at the National Cancer Institute.

Despite the advance made by the new blood test, the number of transfusion-associated AIDS cases will continue to rise, but probably at a steadily decreasing rate, said Dr. James W. Curran, chief, AIDS Branch, Division of Viral Diseases, CDC. That is because the incubation period of the disease is so long—up to 6 or 7 years—and the disease can affect those who received transfusions before the blood tests were introduced.

Dr. Curran also said that transfusion-associated AIDS had been reported in 33 states. He said he thought that compliance with recommendations by high-risk groups to refrain from donating blood may have done as much, if not more, [than the test] to protect the blood supply from AIDS.

Of the 202 transfusion-associated AIDS cases, 82 cases were contracted by hemophiliacs who probably got the disease through the blood plasma product called Factor VIII, a clotting agent. In addition to identifying suspect donor blood, Factor VIII is receiving double protection from AIDS contamination. First it is examined through the antibody test and then a heat-treatment procedure used in manufacturing the plasma products is applied, which has all but eliminated the virus in these blood products.—Joyce McCarthy

NIH and NLM Have New Zipcodes

The NIH campus has been assigned a new Zipcode to go with our Bethesda, Md., address. It is 20892.

The National Library of Medicine has been assigned its own new Zipcode, 20894. This is also a Bethesda, Md., Zipcode.

The new Zipcodes can be used immediately. However, please do not destroy letterhead, envelopes, labels, forms, etc., with the old Zipcodes. Please use up the old supply making the new change in typewriter or pen-and-ink, and when it’s time to reorder, then change to the new Zipcode.

“We hope this will facilitate mail delivery at NIH,” says Bill Arnwine, chief, Travel and Administrative Services Branch, OD, who has been working with the U.S. Postal Service in getting this changed.

According to Mr. Arnwine, the Postal Service recently argued that the Zipcode NIH used was for a Washington, D.C. address. “Getting it changed has been an arduous process, but NIH at last has a Bethesda, Md., Zipcode.”

‘How To Relax’ Seminars Planned By Employee Counseling Service

Stress is feeling under pressure, unable to cope, being overwhelmed by people and circumstances.

The wheels of progress have been turning at higher and higher speeds and, unfortunately, people have wound themselves up tighter and tauter, just to keep pace with it all. No longer do we walk—we run—and even our leisure has become a frantic piling up of activities paced to the ticking of a clock.

Because we are literally running ourselves ragged, we need to take a good look at the art of relaxation. Three, one-hour seminars will be offered by the Employee Counseling Service on Wednesday, Aug. 21 and 28, and Sept. 4 from 12 to 1 p.m., in Bldg. 31, Rm. B2C02A.

Please sign up by calling 496-3164. The group will be limited to 20 participants.

Retirement Deposit For Military Service

In November 1983, NIH employees were notified of procedures to be followed for making a pension deposit for post-1956 Military Service and were advised that the deposit must be made prior to retirement.

Employees planning for retirement were advised to hold/invest the amount of the deposit until Oct. 1, 1985 (or retirement if sooner) since deposits were interest free until that date. FPM letter 83-1-84, dated June 28, 1985, states that no interest will be charged on deposits made before Sept. 30, 1986.

Employees planning for retirement are, therefore, advised to hold/invest the amount of deposit until Sept. 29, 1986. After that date, the deposit will be 7 percent of the military basic pay received for such service, plus interest at a variable rate identified by the U.S. Treasury Department.

Jan Russell (c), first Office of the Director messenger in Bldg. 1, enjoyed a luncheon planned to celebrate her birthday and first anniversary at NIH. Her parents, who do volunteer work at the White House, attended the luncheon. Jan was also the lucky winner of a ‘Cabbage Patch Doll’ presented at the concession stand in Bldg. 31 during the year.

Scott Jones, son of Thomas S. Jones, whose medical illustrations are on display in the main lobby of the National Library of Medicine, recently visited NLM to view the exhibit honoring his father. On display until Oct. 1, the exhibit includes many of the famous illustrator’s original medical works, examples of books and journals in which his illustrations and educational theories appeared, and a selection of nonmedical paintings never before publicly displayed.

The NIH Record

August 13, 1985

Page 3
Part-Time DRR Staffer Proves a Computer Whiz

Building a better mousetrap was never one of Eric Greenberg's goals. But, symbolically speaking, he built one anyway. In fact, Greenberg's brainchild—Tablecalc, an innovative software package enables administrators to better manage and track institutional grants—is so highly regarded that it is being used throughout NIH, not just in the Division of Research Resources where he devised it. It is also being adopted for use by the Department of Agriculture and Defense, and the Nuclear Regulatory Commission.

Besides conceiving and writing Tablecalc and other computer programs, Greenberg has also been intimately involved in other computer-related activities for the Data Management Section of DRR.

"Eric's really involved in a lot of projects," says Ric Shafer, DRR executive officer.

"Tablecalc," says Shafer, "has provided us—and others outside the division—with a software package which makes it easier to get the computer to do what you want it to do.

"His second major contribution is that he essentially has become the division's PC (personal computer) expert; he's helped the staff understand the power and capabilities of PCs, as well as tutored them on how to use various applications. He's even written a handbook which uses layman's terms to describe how to operate a PC."

Greenberg has also helped procure new computer equipment by evaluating and testing different models. He is currently upgrading the division's report producing information systems using WYLBUR's command procedures, which greatly reduces the number of commands required.

"And by using this higher level program language, we are able to decrease processing time, thus increase efficiency," Shafer added.

Because of his accomplishments, the division recently presented Greenberg with a sizeable Special Act or Service Award, a rare achievement for a part-time employee.

Part-time? Yes, part-time.

You see, what's remarkable about this story is that because Eric attends school full-time at the University of Maryland in College Park, he only works 10 to 15 hours a week at DRR.

"I'm an EE (electrical engineering) major," says the 22-year old honor student; "and I'm going to graduate in December."

"Originally, I was told to sit down at my desk with a ruler and pencil and edit lines of computer programs, correct errors in how programs were written.

"But I couldn't see wasting my time doing that when I knew there had to be easier ways. So I wrote a computer program to do the editing. From then on, every time Jean (Jean Babb, Eric's supervisor) gave me something to do, I'd write a program to do it."

"I've never been the rebellious type," he says, "but I knew I could figure out a way to use my mind to make the job easier. I guess I'm better at using my mind than I am at taxing my patience."

Once the range of Eric's talents and skills became evident, the complexity of his job ballooned. And he's happy for the opportunity.

"Not only has the job been great in that the Division has been extremely flexible in permitting me to work around my classes, but the job has been beneficial because I can show prospective employers something tangible when I begin interviewing this fall," Greenberg noted.

A lot of people throughout the Division will miss Eric Greenberg when he graduates. "We've been fortunate to have him," says Shafer, "he's done much more than we ever imagined."

---Michael Fiuharty---

Dave Lynch, Crew Win Regatta; Sailing Lessons Start in Sept.

Dave Lynch skipped the 19-ft. Flying Scot Wingit to victory in the first of four NIH Sailing Association (NIHSA) regattas for 1985. His crew; Amy Rosenberg and Karl Arrington.

The NIHSA's Basic Training Course, including six Wednesday evening classes and three on-the-water sessions, will start Sept. 4. Cost is $75 plus $30 NIHSA dues.

Sign-ups will be Aug. 28 at 9 a.m., Bldg. 31, R&W Activities Desk, where more information on the NIHSA and the Basic Training Course is available.
Cyclosporine Being Tested by NEI and LSU
To Improve Corneal Transplant Success Rate

A drug that may help to improve the success rate of corneal surgical transplants is being tested in a study underway at the National Eye Institute’s Clinical Branch and the Louisiana State University Eye Center.

Although corneal transplantation is considered to be the most successful transplant operation known—corneal grafts have restored sight to hundreds of thousands of people—5 to 20 percent of the implanted grafts are rejected. To be eligible for the first clinical trial of cyclosporine in corneal transplant patients, candidates must have had at least two previous corneal transplants which failed to survive, or there must have been one failed graft in a person with corneal problems affecting both eyes.

Cyclosporine, on the other hand, appears to inhibit only a portion of the patient’s immune system. Unlike other immunosuppressive agents, this drug does not cause a significant reduction in the number of white blood cells of the B type, which are needed to produce infection-fighting antibodies. And though cyclosporine can be toxic to the kidneys and liver, the drug will be given for such a short time in this study it is believed that any side-effects would be reversible.

To be eligible for this first clinical trial of cyclosporine in corneal transplant patients, candidates must have had at least two previous corneal transplants which failed to survive, or there must have been one failed graft in a person with corneal problems affecting both eyes. The conditions, for which a corneal transplant may need to be performed include: congenital abnormalities, scarring due to injury, and corneal dystrophies such as keratoconus (a protrusion of the center of the cornea).

To be considered for the study—which is sponsored by Sandoz, the manufacturer of cyclosporine—patients must be referred by a physician. Referrals may be arranged by calling Drs. Manuel Datiles, Leslie Fujikawa, or Robert Nussenblatt, at (301) 496-3123.

According to the Eye Bank Association of America, about 25,000 corneal grafts were transplanted last year in the United States. The vast majority of them survived, restoring useful vision. Even so, graft rejection is common in certain high risk patients, and once the first graft fails to “take,” rejection of the second graft is more likely.

Dr. Wm. Zukel, NHLBI, Awarded Honorary Degree

Dr. William J. Zukel, deputy director of the Division of Heart and Vascular Diseases, NHLBI, has been awarded the honorary Doctor of Science degree by the Council on Higher Education, University of Puerto Rico School of Medicine.

The award was conferred for Dr. Zukel’s “contribution to humanity in the area of science and health,” and because he has been “instrumental in promoting research, especially in the field of cardiovascular diseases, and particularly in helping the people of Puerto Rico.”

He was presented the honorary degree by the president of the University of Puerto Rico at the graduation ceremonies of the medical sciences campus held in San Juan on June 7.

Dr. Zukel began his career at NIH in 1957 when he was appointed assistant director of the then National Heart Institute. He has held a succession of posts within the Institute and has been the prime mover in planning and coordinating several of the major international epidemiologic studies and clinical trials carried out by NHLBI.

He was awarded the PHS Meritorious Service Medal in 1974, and the Distinguished Service Medal in 1983.

A native of Massachusetts, Dr. Zukel received his M.D. degree from Hahnemann Medical College in Philadelphia, and his doctorate in public health from the London School of Hygiene and Tropical Medicine. He is a member of numerous professional societies and has published extensively.

Win Welsh, Secretary, OC
Retires After 16 Years

Winifred H. Welsh, secretary to the Associate Director for Communications, OD, retired on Aug. 2, after 16 years of Federal service.

Win, as she is affectionately called by her colleagues and friends, has worked in the Office of Communications for the past 6 years.

A native Washingtonian, Win graduated from the Washington School for Secretaries and obt...
Three DRG Staff Members Retire With Combined Federal Service of 71 Years

Dr. Kornfield

Three members of the Division of Research Grants, Dr. Lottie Kornfield, Irene Lyddane, and Dolly Douglas of the Statistics and Analysis Branch, recently retired with combined Federal service of 71 years.

Dr. Kornfield, executive secretary of the Immunological Sciences Study Section since 1974, entered Federal service in 1963, as a research microbiologist with the Naval Radiological Defense Laboratory in San Francisco.

She received her Ph.D. degree in 1960 from the University of Chicago, where she was a National Science Foundation Cooperative Graduate Fellow.

Dr. Kornfield plans to return to the San Francisco area where she lived until she came to Washington.

Ms. Lyddane, a grants clerk in the Referral Section, spent her entire career of 23 years in DRG. First, she worked as a clerk in the fellowships committee of the Career Development Review Branch and after the branch was abolished, in the Referral Office.

She received several performance awards during her career and says she was lucky to work with nice people over the years.

She plans to take 2 months to visit members of her large family and afterwards, work part-time at the National Cathedral.

She also hopes to have time to return to commercial art which she studied earlier. An avid sports fan, she plans to watch various games, including upcoming Redskin games.

Ms. Douglas, a program analyst in the Report, Analysis, and Presentations Section, SAB, started her Federal career as a secretary in the Department of Defense where she worked for 11 years before coming to DRG in 1971.

In DRG, she was involved in providing statistical data on NIH extramural activities for publication in the NIH Data Book and the Extramural Trends, two resource publications used by NIH management and others.

Ms. Douglas plans to travel and pursue her many hobbies which include art and antiques collecting.

Three Members Appointed to NIGMS Advisory Council for 4-Year Terms

Dr. Theodore R. Sherrod, professor of pharmacology at the University of Illinois College of Medicine in Chicago. Ms. Barbara A. Gill, state senator for Maine's 32nd District (Portland) and Dr. Oliver Smithies, professor of genetics and medical genetics at the University of Wisconsin in Madison, have been appointed to the National Advisory General Medical Sciences Council for 4-year terms.

The Council, which meets three times a year, is composed of leaders in the biological and medical sciences, education, and public affairs. Its members review applications for research and research training grants and make recommendations.

The National Institute of General Medical Sciences funds research and research training in the basic biomedical sciences. This support enables scientists at universities, medical schools, and research institutions throughout the country to work to expand knowledge about the fundamental life processes that underlie human health and disease.

Dr. Sherrod is a pharmacologist with research interests in cardiovascular and renal pharmacology. He received an A.B. degree from Talladega College, an M.S. degree in organic chemistry from the University of Chicago, and his Ph.D. and M.D. degree from the University of Illinois College of Medicine. He has served on the faculty of the University of Illinois College of Medicine since 1944.

He also serves on numerous committees including the University's Hospital's committee on pharmacy and therapeutics and on the board of directors of the Chicago Lung Association and of the John Crerar Library in Chicago.

He holds membership in the American Society for Pharmacology and Experimental Therapeutics and the American Society for Experimental Medicine and Biology.

Ms. Gill is the special projects coordinator at the Osteopathic Hospital of Maine in Portland. She is also a member of the Maine legislative council, and serves on the national conference of state legislatures and the council of state governments, eastern regional conference.

As a state legislator, she is an active participant in the HHS National Center for Health Services workshops dealing with various health issues. Ms. Gill is currently a member of the board of directors and a former president of the St. John's Federal Credit Union of South Portland, Me.

She attended the University of Southern Maine and trained as a laboratory technician at several hospitals in Maine. Ms. Gill is former owner and manager of Gill's Leader Drug Inc.

Dr. Smithies is a geneticist studying aspects of the regulation of gene expression. He received his B.A. degree in physiology and M.A. and Ph.D. degrees in biochemistry from Oxford University.

Since 1960, he has been on the faculty at the University of Wisconsin at Madison, where in 1971, he was appointed the Leon J. Cole professor of genetics and medical genetics.

In 1980, Dr. Smithies became Hilldale professor of genetics and medical genetics. In 1971, he was elected to the National Academy of Sciences and in 1978 to the American Academy of Arts and Sciences.

He is recipient of many other honors including the Founders Award of the Electrophoresis Society and the Karl Landsteiner Memorial Award of the American Association of Blood Banks in 1984. Dr. Smithies is a past president of the Genetics Society of America.

R&W Plans Weekend Sail

Join R&W for a weekend sailing trip on the Chesapeake Bay, Aug. 23-25. Sailboat, rental, captain, cook, breakfast and lunch on Saturday and Sunday are included in the price of $105 per person.

Participants will meet at Annapolis Harbor Marina between 6 and 7 p.m., Friday, to load gear onto the boats. On Saturday they will sail to St. Michaels to enjoy this quaint historic town and will return to Annapolis on Sunday at approximately 5 p.m.

Sign up at the R&W Activities Desk, Bldg. 31.
New Technique, Funded by NIGMS, Being Developed To Quickly Identify Disease-Causing Microorganisms

When a patient arrives at a hospital suffering from a severe infection, doctors need to start treatment immediately. Often they must do this without knowing—for at least a day or, in many cases, much longer—exactly what is causing the infection. The choice of treatment is based on the patient’s symptoms and history, and on the physician's experience. Since various disease-causing fungi, bacteria, and viruses respond differently to different modes of treatment, it is important that the physician choose the right treatment. In some cases the clinical microbiology laboratory—that part of the hospital responsible for the isolation and identification of microorganisms—can, by microscopic examination of the patient's blood specimen or other body fluids or by how such a sample reacts to certain chemical staining techniques, make a relatively speedy report.

Infectious Organisms

Also, many infectious organisms can be cultured, or grown, from the specimen in less than a day and then identified using one of many different assay systems that are available. These systems may take a few hours to pinpoint the cause of an infection, providing there are a large number of organisms in the specimen. However, there are many organisms, such as those that cause meningitis, gonorrhea, and Legionnaire's disease, that are difficult to grow or grow very slowly. Identification of some infectious agents can take weeks.

Clearly, any system of identification which would cut the total time required for a confirmed diagnosis could save both lives and money.

At Los Alamos National Laboratory in Los Alamos, N.M., National Institute of General Medical Sciences grantee Dr. Gary Salzman and co-investigator Dr. Charles Gregg, are working on such a system which could identify microorganisms in minutes without first requiring that they be isolated and cultured.

At present, those assay systems most widely used to identify microorganisms depend on “tagged” or labeled substances that bind specifically (form a chemical union) with a particular infectious organism or an antibody produced by the host to that organism. An antibody is tailored to fit the infectious organism or antigen the way a key fits a lock.

Binding Step Essential

The binding step is the essential event needed to identify the microorganism. After the antibody binds to the antigen portion of the organism, the unbound matter is washed out of the specimen and the assay is performed. The specific tag used may be a radioactive chemical, a fluorescent dye or an enzyme. The organism with its tagged antibody can be detected with an assay designed to specifically measure radioactivity, fluorescence or enzyme activity.

Although these so-called immunoassays for rapid identification of the cause of an infection have been greatly improved recently, they still take several hours to complete.

Dr. Salzman's system, which grew out of his basic studies of the scattering of light from cells, involves principles quite different from any previously used in clinical microbiology. He employs a technique known as MLS (for multi-parameter light scattering) to analyze how specimens interact with polarized light.

Light from a laser passes through a polarizer and then through a modulator. This bends the polarized light to the right and left in a circular fashion.

When a biological sample is placed in the device, the pattern of light scattered by the sample is measured by a spectrometer (an optical instrument for measuring light). The device can use different signal frequencies, each of which brings additional information to aid in identification of the organisms in the sample.

Dr. Salzman believes his system works by recognizing the “packaging” of the genetic material that is unique for each microorganism. Since the genetic material of biological specimens like bacteria, fungi, or viruses is asymmetric, it interacts differently with polarized light coming from different directions.

By making many observations and using a computer to tally the results, Dr. Salzman's system has shown remarkable ability to distinguish among very closely related organisms like the viruses from various forms of influenza, dengue fever (a tropical disease), and encephalitis.

Dr. Salzman's present device is a stationary instrument in which the viruses and bacteria in the specimen are identified in a test tube. He is now planning to combine the MLS device with a flow cytometer—a machine that sorts cells extremely rapidly—in order to determine in a matter of minutes, both the identification and an estimate of the relative quantities (numbers) of microorganisms in samples which contain many different types of organisms, as do most clinical specimens.

Diagnosis Time Shortened

The shortened time it will take to make a diagnosis with this system should prove valuable in the treatment of many diseases, including spinal meningitis, septicemia, pneumonic plague, and Legionnaire's disease, illnesses for which prompt diagnosis is particularly important for effective therapy.

In some situations it might prevent unnecessary invasive intervention, such as the performance of a Cesarean section in a pregnant woman who has lesions resembling herpes and who is about to deliver a child.

In addition to possibly reducing the incidence of death or permanent damage due to infection, such rapid diagnosis may shorten the time spent in the hospital, and help hospitals better control the spread of infection.

Practical development of the device for clinical use will be supported by Mesa Diagnostics, a private firm which hopes to have this system ready for marketing by 1987. —Doris Brody

Retirement Planning Program

The Recruitment and Employee Benefits Branch, DPM, is offering another Retirement Planning Program for NIH employees on Oct. 31 and Nov. 1. A Personnel Bulletin will be distributed desk-to-desk giving more detailed information.

Dr. Watzman Receives Honor

Dr. Nathan Watzman, chief, Clinical Sciences Review Section, Referral and Review Branch, Division of Research Grants, was recently honored as the 1985 Distinguished Alumnus of the University of Pittsburgh School of Pharmacy.

Dr. Watzman was also an invited lecturer at a seminar for the Pharmacy School’s graduate students and research faculty, in which he discussed the types of NIH funding, the support mechanisms and programs available to researchers in the pharmaceutical sciences, and the NIH Peer Review System.

Dr. Watzman received his Ph.D. in pharmacology from the School of Pharmacy in 1961, after which he became assistant professor of pharmacology at Northeast Louisiana State College School of Pharmacy. In 1963, he returned to the University of Pittsburgh as an assistant research professor of pharmacology, progressing to associate professor of pharmacology.

Joined NIH in 1968

He joined NIH in 1968 through the Grants Associates Program. After completing the 1-year internship in federal science administration, Dr. Watzman joined the Health Resources Administration as program officer in the Bureau of Health Professions Education and Manpower Training where he supervised the review and management of grants and contracts to schools of optometry, podiatry, pharmacy, and veterinary medicine.

In 1981, he became executive secretary of the Respiratory and Applied Physiology Study Section in DRG, assuming his present position in 1984.

Dr. Watzman has received several honors, including the Department's Superior Work Performance Award in 1972 and 1975 and Outstanding Work Performance Award in 1976. In 1978, he received a Honorary Doctor of Science from the New York College of Podiatric Medicine.

A registered pharmacist in the States of Maryland and Pennsylvania, Dr. Watzman has served as science publication reviewer to the Journal of Pharmaceutical Sciences.
Nature is crowded with examples of the effects of biological clocks. Migration, hibernation, and courtship are dependent on these timing systems to a large extent. A biological clock, or biological rhythm, can be defined as an innate process in an organism that causes regular cycles of function or behavior. These cycles may be 24 hours (circadian), or longer. Scientists know that biological rhythms are innate because they exist in the absence of environmental cues, such as the 24 hour day/night cycle.

Scientific literature contains many references to animals that change their behavior only by response to environmental cues, such as the 24 hour day/night cycle. Yet when *Gonyaulax* were kept in constant light for several weeks, they maintained their usual cycle of energy acquisition as if they were still experiencing daylight only every 12 hours.

From this and many other examples, researchers know that these rhythms have a biological basis.

Although biological clocks occur in numerous species (including humans) and have been studied for more than 30 years, scientists know little about their biological or physiological basis.

In some organisms scientists have found certain areas of DNA (one component of chromosomes) that contain genes which, when they undergo mutations, change the individual’s biological rhythms. Isolation of the mutations that change biological rhythms has made analyses of these phenomena at the molecular (DNA) level possible.

National Institute of General Medical Sciences grantees Drs. Michael M. Rosbash and Jeffrey C. Hall, and their colleagues at Brandeis University in Waltham, Mass., are studying genetic mutations that disturb circadian rhythms in *Drosophila melanogaster* (fruit flies).

Studies of the genetic basis of behavior, such as circadian rhythms, in lower animals can provide information useful for human applications. Researchers study invertebrates—members of the animal kingdom that lack a backbone—such as *Drosophila* because they are less complex and better understood developmentally and genetically than any vertebrates. Eventual understanding of how genetic factors affect complex behavior in higher organisms, including humans, depends largely on the progress scientists make now, studying invertebrates.

Dr. Rosbash and his colleagues are working with one area of the fruit fly X chromosome (one of the four types of fruit fly chromosomes) called the “per” (period) locus. (A locus is the place on a chromosome where any form of one particular gene resides.) Two of the most studied behaviors known to be changed by “per” mutations are circadian rhythms of fly activity (flies normally are active during the day, not at night), and the rhythmicity of male courtship songs. Different mutations at the “per” locus will lengthen, shorten or abolish these biological rhythms.

From observation, scientists know that when “per” DNA is broken in particular places, predictable changes in the fruit fly’s biological rhythms result. To learn more about these effects of “per” mutations, the scientists used recombinant DNA methods to transfer different subsections of “per” DNA from normal flies to mutant flies that lacked circadian behavior. Dr. Rosbash and his coworkers hoped to restore biological rhythms to the mutant flies.

The researchers found two particular overlapping “per” DNA fragments each of which restored circadian behavior to mutant flies that had lacked it. This was significant because it was the first time that DNA transferred from one higher (multicellular) organism to another effectively “rescued” a mutant by restoring its normal behavior. Moreover, the scientists had had no knowledge of the gene product (protein specified by the DNA) that caused this “rescue,” which complicated the experimental strategy. Exactly how these transferred DNA sections (or, the proteins that they represent) affect circadian rhythms remains to be determined.

Another goal of Dr. Rosbash’s research is to determine the genetic regulatory components that turn circadian behavior on and off, and how this DNA sequence has diverged in the evolution of the various species of *Drosophila*.

These studies will involve transfer of the normal “per” DNA from another species of fruit fly, *Drosophila simulans*, to see if it will restore biological rhythms in mutant *Drosophila melanogaster*. The scientists are also interested in whether the mutant fly will regain biological rhythms characteristic of its own species, *melanogaster* or those of the donor fly, *Drosophila simulans*.

Dr. Rosbash believes that evolutionary divergence may account for differences among the various species’ biological rhythms.

Dr. Rosbash’s research is an important first step toward determination of the genes that are the physical basis of the organisms’ ability to live by internal clocks. His research promises significant breakthroughs in understanding the genetic regulation of behavior and development.—Sandy Hecker

---

**Literature Searches**

Current bibliographies on subjects of widespread interest are available without charge from the National Library of Medicine’s Reference Section. The bibliographies were produced through NLM’s computer-based MEDLARS system and contain references from recent medical journal literature. A complete list of available Literature Searches is published each month in Index Medicus and Abridged Index Medicus.

When requesting Literature Searches, please include title and number, enclose a self-addressed stamped envelope, and mail to: Literature Search Program, Reference Section, National Library of Medicine, Bethesda, MD 20205.

The newly available bibliographies follow:


---

The NIH-based Bethesda/Medical Chapter of the National Contracts Management Association has recently begun its second year and has elected officers installed by Jack Higgins, retiring National President. Officers are (l to r): Betty Nordan, treasurer; Claire Marwick, president; Mr. Higgins, installing officer; Gloria Dahl, vice president; Sharon Miller, secretary. (Curtis Tate, chapter director, is not shown.) Meetings are held at lunchtime, the third Wednesday of each month, at the National Library of Medicine. Further information may be obtained by calling Claire Marwick, (301) 496-4637.
Native Americans Announce Indian Awareness Program

NIH Native Americans have announced the 1985 American Indian awareness program to be held Sept. 25-27.

Programs will be held in Masur Auditorium starting at 11:45 a.m. each day. Speakers will include: on the 25th, Ray Haberlin, a tribal leader of the Oneida National of New York, on "the Iroquois Confederacy"; on the 26th, Wanda Wood, president of the Maryland Chapter on the North American Indian Women's Association and its objectives; and on the 27th, Mitchell Bush, president of the American Indian Society, Washington, D.C. on "The Urban Indian."

The well-known Apache Crown Dancers from the Mescalero reservation in New Mexico will perform traditional Apache songs and dances between 12:40 p.m.-1:15 p.m. on all three days.

Indian Arts and Crafts including bead work, pottery, silver, leather craft and traditional dress will be on display in the Clinical Center Information Office's balcony museum as well as the Bldg. 31A patio between 10:30 a.m. and 2 p.m. on all three days.

Arts and crafts persons will be happy to answer such questions concerning their displays as:

- Why an Indian never closes a circle in his or her arts or crafts work?
- What is proper teppee etiquette? Why is it still observed during ceremonies today?
- What do the Eagle, Bear, Buffalo, Owl and other animals mean to an Indian, even today? □

Two NIADDK Program Directors Share American Diabetes Association Award

Jean Curran, diabetes research program director in the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases (NIADDK), and Dr. Keitha K. Krueger, NIADDK diabetes centers program director, shared the American Diabetes Association's Charles H. Best Medal this year for outstanding service to the field of diabetes. Five other individuals were corecipients of the award, among them, Dr. Lester B. Salans, former NIADDK Director.

The medals—named for the codiscoverer of insulin—were presented at the 45th annual meeting of the American Diabetes Association (ADA) in Baltimore in June.

R&W Plans Trip to Hilton Head

R&W is planning a trip to Hilton Head, S.C. for Veterans Day Weekend. The bus leaves NIH on Friday, Nov. 8, at 7 a.m. and leaves S.C. for the return trip on Monday, Nov. 11 at 7 a.m. The cost is $130 per person (based on double occupancy) and includes three nights at the Hyatt Hotel on Hilton Head Island and round trip transportation.

Sign up at the R&W Activities Desk, Bldg. 31. □

Bowling League Meets Aug. 28

The next meeting of the NIH mixed bowling league will be held on Wednesday, Aug. 28, at 7 p.m. at Brunswick River Bowl. The first league play will begin Sept. 4 at 6 p.m.

To sign up for a team or for more information, call Ralph Isenberg, 496-3609. □

Instead of loving your enemies, treat your friends a little better.—E.W. Howe
In 1961, he initiated the program in clinical research on cholera in Dacca, East Pakistan (now Bangladesh). At Dacca, he instituted a new therapy for patients with cholera, drastically reducing the mortality from this disease.

He returned in 1964 to become Clinical Director, National Institute of Arthritis and Metabolic Diseases (now the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases), and then Director of the Clinical Center, NIH, until 1975.

After completing his study at Johns Hopkins University, he rejoined NIH in 1976 as Special Assistant to the Director, NIH, concerned with inter-Institute policy and management issues in epidemiology, clinical trials, and health effects of environmental hazards.

At the request of the Director, he convened the NIH Working Group on acquired immune deficiency syndrome (AIDS) in the spring of 1982, and was a member of the PHS Executive Task Force on AIDS. He was the key NIH coordinator for AIDS research and liaison to the Centers for Disease Control and the Food and Drug Administration, as well as all other PHS agencies.

**Unique Individual**

Dr. Gordon was viewed as a unique individual at NIH in that his breadth of knowledge in clinical sciences made him the chief advisor in this area to the past two NIH Directors.

Throughout his clinical career Dr. Gordon was interested in epidemiology, and it was this interest and dedication that allowed him to organize and oversee the highly regarded PHS Epidemiology Training Program.

His dedication to this program has permitted young medical trainees to receive specialized training in epidemiology and biostatistics, thereby helping the United States to reduce a significant manpower shortage in this important area.

His combined interest in basic and clinical sciences also made him a leading authority on facilitating the translation of bench science into clinical practice.

**Varied Writer**

Dr. Gordon wrote on a variety of subjects in the scientific literature, and received several awards, most recently, the Department of Health and Human Services Award for Exceptional Achievement. Among these were the American College of Epidemiology, the Society for Epidemiologic Research, and the Society for Clinical Trials, of which he was president from 1981 to 1983.

He was a member of St. Luke's Episcopal Church, Bethesda. Survivors include his wife, Elizabeth, and four children: Hilary Gordon of Portland Me; Dana Dixon of Cleveland, and three grandchildren. He is also survived by his mother, Mrs. Robert S. Gordon of New Jersey.

**Updated Animal Care Guide Available for Distribution**

A revised edition of the Guide for the Care and Use of Laboratory Animals is now available for distribution, according to Dr. William Gay, director of the Animal Resources Program of the National Institutes of Health (NIH). The new version replaces the initial edition in 1963, the Guide has become widely recognized as the primary reference on standards of animal care in scientific institutions.

Last revised in 1978, the Guide was updated recently by a special committee of the Institute of Laboratory Animal Resources of the National Academy of Sciences to reflect the policy of the Department of Health and Human Services (DHHS) on the care and use of animals used in research experiments.

Besides improving its bibliographic, the latest edition makes recommendations for new methods of cage ventilation and other housing requirements, including a few revisions in cage sizes.

The new version of the Guide also goes beyond previous editions in adding specific references to support their recommendations and defining more specifically many of their recommendations.

The Guide includes, as an appendix, a statement of principles developed by the Interagency Research Animal Committee (IRAC), a group of Federal agencies that use research animals in the programs they support. In addition to NIH, other members of IRAC include: Departments of Agriculture, Defense, State and Interior; the Environmental Protection Agency; National Aeronautics and Space Administration; National Science Foundation; and Veterans Administration.

Since the Guide first appeared, more than 300,000 copies have been distributed to all kinds of scientific institutions. A copy of the latest edition of the Guide may be obtained from the Office of Science and Health Reports, Division of Research Resources, Bldg. 31, Rm 5B-10. Bulk copies of the publication should be obtained directly from the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402. The GPO publication number for the Guide is 017-040-00498-2.

**ANIMALS**

very good. And we think animals are a very valuable resource and ought not to be used unnecessarily.

Q. That's my next question. Given that we are dealing now, we are going to have to use some animals in experiments, what can we do to eliminate unnecessary pain and unnecessary trauma in those necessary experiments that we may not be doing now?

A. Well, what can we do that we're not doing now, I'm not so sure.

But let me tell you some of the things we are doing. Under our new policy, before NIH will even accept an application it must be reviewed by a committee in the [potential grantee's] institution that assures us that the number of animals is not unnecessarily large or too small to get good results because, either way, animals might be wasted. Secondly, there must be reasons why a given species is used in the research. Where possible, species lower on the phylogenetic scale are preferred over species that are higher and so there is an emphasis on not using the more complex organisms in research.

Finally, here at NIH the peer review system seeks justification for the use of animals.

So all kinds of protection are built into the system and if a question is raised anywhere—then we put a hold on that and that research cannot be funded until we have resolved the question.

Q. What agency or office within NIH is in charge of the overseeing of intramural care and use of animals within NIH's own laboratories?

A. That comes under the NIH Animal Research Committee that is chaired by Dr. Robert A. Whitney Jr. and it reports to Dr. Joseph S. Rail, the Deputy Director for Intramural Research. So, they have that responsibility. Now their policy was developed and published prior to the new Public Health Service's policy but on all significant points the two policies are in agreement. So we don't have two sets of standards—one for the intramural (inside NIH) and one for the extramural—but there are some technical details in which they are different. Generally speaking, they agree.

Q. That brings us to the extramural system: the animals and their use in laboratories and institutions outside NIH which funds the projects. Who oversees them and how do they go about it?

A. That part is overseen by the Office for Protection from Research Risks (headed by Dr. McCarthy himself). And our office, although located organizationally at NIH, has responsibility for all animals that are involved in research supported by any of the Public Health Service agencies. So it is Public Health Service policy that we implement, not simply an NIH policy—though because NIH is the biggest—it's sometimes referred to as the NIH policy.

But NIH is not a regulatory agency as such, designed to impose penalties, is it?

A. That's why we do this in the name of the Public Health Service which has delegated regulatory responsibility from the Secretary.

Q. So, if you find something in an NIH or PHS grant that is wrong, NIH does have a regulatory power.

A. It comes to the equivalent of that. We implement what is called "policy" and the policy for practical purposes is little different than a regulatory power.

(Continued on Page 11)
We received that evidence on May 23 of this year and it consisted of approximately 80 hours of videotape, which had to be carefully analyzed. So between May 23 and mid-July most of that tape was reviewed up to five times and documentation was made on every single animal and the treatment of every single animal; some 47 animals were depicted on the tape and we then completed a report based on our analysis of the entire set of tapes. We think the investigation of that was completed in a short time once the evidence was in hand. But the evidence was stolen one year prior to its being turned over to the NIH.

Q. Assuming you find there is some violation of the rules and regulations in a given project—and that it warrants some kind of penalty—what are the different kinds of things you would consider doing to them?

A. Well, we try to make the punishment fit the crime. There are two categories of noncompliance: the first and the more common, is that an institution's administration of its animal policy or facilities has fallen below acceptable standards. In that case, we hold the institution responsible for bringing the policies or facilities into compliance with the Public Health Service policy.

In a few cases, the facilities and the institution may be functioning properly but the investigator has broken the rules. In which case, we try to make the sanctions pertain to a given project or to a specific investigator since it doesn't seem to be the entire institution that's out of line.

Q. So NIH has adequate, ample power to remedy malpractices when it finds them.

A. Yes, but we feel that our investigations have to be very carefully carried out because in the event that we have negative findings, the accused have the right to appeal. Those appeals are reviewed according to very rigorous administrative procedures and consequently the evidence has to have must be conclusive. So we cannot—simply on the basis of casual allegations—bring about sanctions. If we can develop demonstrable evidence, then we take appropriate action. These inquiries and investigations are carried out, at least from our point of view, in a confidential manner. Frequently, the institution or the investigator will deny the statements to the press so not all of them are carried out in a confidential manner. But, so far as we're concerned they're to be treated confidentially and the results are made public only when we have completed the investigation.

Q. So if there is any statement before conclusion of the investigation it would be on the part of the individual investigator?

A. That is correct. It should be made clear that in the implementation of our policy we rely primarily on the statement of each institution that they will be in compliance with the policy and we accept that on good faith. We're not quite so naive as to think that simply putting something on paper always means that institutions are going to be in compliance. Consequently we do have a series of site visits to randomly selected institutions.

We've carried out approximately 18 of these since 1983 in addition to investigations for cause and we are continuing to carry out random site visits. That's still a small percentage of a total number of institutions but the word is out in the community that any institution is subject to receiving a visit virtually unannounced.

When we visit a site, what we look at are administrative records going back three years, minutes of the animal care committee going back three years. We interview investigators, veterinarians and members of the Institute's Animal Care and Use Committee. We look at the facilities, we check the records of when food was procured, when cages were procured and check these against the arrival of animals and so on. It is of course that our site visits concentrate on is not particular shortcomings but on the quality of the administration of the program and that's the difference from USDA. USDA looks for specific shortcomings: the cage is dirty or rusty, the cagewasher doesn't work, etc.

What we look at is, does the institution have an appropriate administrative structure to deal with problems that inevitably are going to arise in an animal program? Do they have a good engineering staff so that if something breaks it will be immediately fixed? If the plumbing gets plugged with animal hair will it be corrected immediately? Do they have a way of obtaining a new cagewasher if the old one breaks down?

Is there central procurement so that an investigator can order animals and not have them waiting out on the loading docks in wooden crates because the cages haven't arrived yet?

Those are the kind of questions that we look at; we try to get at the root of the matter.

Q. Under new regulations with more random site visits and an intensified education program, what specific things can you think of that will make it more likely there will be improved future care and use of laboratory animals?

A. Well, I think ultimately, we need to get away from a regulatory stance and stress an educational effort and to that end we held a national symposium last year. We have followed up with regional meetings around the country. We have begun a process and have scheduled 8 regional meetings in this calendar year and will continue to hold these regional meetings.

We will try to reach investigators, administrators, veterinarians and other persons who have responsibility for running a good program. And we think ultimately the way to make sure that we have good programs is to sensitize people. We feel we would prefer not to do that through disciplining them or punishing them but rather through educating them. We do not consider ourselves so much a regulatory office as an educational and sensitizing office and we think that is ultimately the way to make something happen.

'Distinguished Nurse Lecture' Announced by CC Nursing Dept.

The Clinical Center Nursing Department has announced a new lecture series, "The Distinguished Nurse Lecture," The series will provide a national forum for discussing important issues in the provision of nursing care.

First speaker for the series will be Dr. Jean E. Johnson, R.N., a nationally known scholar in nursing with extensive research experience in patient care.

First lecture of the new series will be presented at 9 p.m., Wednesday, Oct. 16, at NIH's Clinical Center, ACRF Amphitheater. A reception will follow. For further information, call (301) 496-6012.
A clinical trial of an immunosuppressant drug that may stabilize patients with chronic progressive multiple sclerosis has begun at NINCDS and 11 other centers throughout the country.

Cyclosporine, the drug under study, selectively inhibits one type of white blood cell in the immune system which is the body’s main defense against foreign invaders. Normally, when these cells detect bacteria, viruses, or transplanted organs they signal other immune system cells to mount an attack. Cyclosporine blocks one of the signals that is crucial to the formation of immune cell armies.

Since the mid-1970s, transplant patients have been receiving cyclosporine to prevent their immune systems from rejecting new organs. Recent evidence suggests multiple sclerosis patients may have an abnormal immune response in which the immune cells attack myelin, the coating on nerves in the brain and spinal cord.

"Since cyclosporine works so well at decreasing the immune response in transplant patients, it is reasonable to assume that it may suppress any possible immune system attacks on myelin," says Dr. Henry McFarland of the Institute’s Neuroimmunology Branch, who is running the drug trial at the NINCDS center.

Somehow in multiple sclerosis the myelin sheath insulating nerve cells in the central nervous system is destroyed and replaced by scar tissue. People with multiple sclerosis experience a wide variety of symptoms depending upon which nerve cells are affected. The most common problems are weakness, numbness, and difficulty with coordination.

For the majority of patients, multiple sclerosis symptoms wax and wane. Approximately 30 percent, however, have symptoms that steadily worsen without remission. It is these “chronic progressive” patients on whom cyclosporine is being tested.

In small, preliminary trials completed last year in Europe, the drug appeared to stop advancement of the disease in chronic progressive patients. The promising evidence of a stabilizing effect convinced Sandoz Ltd., the Swiss pharmaceutical company that patented cyclosporine, to sponsor a larger trial.

Each center in the current study will follow 40 to 60 patients who will be randomly assigned to take a placebo or cyclosporine for 2 years. Neither the physicians nor the patients will know who is receiving which treatment. Medication and funds to conduct the study are being supplied by Sandoz.

Dr. Henry McFarland of the NINCDS Neuroimmunology Branch evaluates the coordination of a patient participating in the cyclosporine trial.

"This is a rigidly designed, definitive trial," says Dr. McFarland. "It should provide a definite answer that yes, cyclosporine works for multiple sclerosis and let’s treat more patients; or no, it doesn’t work, so let’s move on to something else."

Multiple sclerosis is difficult to treat because it is so unpredictable. One patient may be confined to a wheelchair, while another walks unaided. Symptoms that at times may be mild later can become debilitating, and serious symptoms can spontaneously improve giving patients false hope of a cure.

"Multiple sclerosis is unlike cancer, where in most cases you know how the disease progresses," says Dr. McFarland. "If you increase the survival time of a leukemia patient, you know you’re successful. With multiple sclerosis it’s difficult to tell whether you’ve been successful, or the disease has improved on its own."

Although cyclosporine is perhaps the most effective and selective immunosuppressant known today, it is not without side effects. The drug has been known to affect adversely the kidneys’ ability to cleanse life-threatening waste products from the blood.

Most studies, however, indicate that the drug’s effect on the kidneys is temporary and that the cleansing ability of the organs will return to normal after the dose is lowered or the medication stopped. All patients participating in the Sandoz drug trial will receive kidney function tests to detect any toxicity.

Patients are still needed at the NINCDS center, says Dr. McFarland, but candidates for the study must be referred by their physicians. Chronic progressive multiple sclerosis patients who have shown a general decline over the past year may be eligible for the trial. Since many of the neurological tests of disease progression rely on mobility, physicians should recommend candidates who are able to walk.

In addition to participating in the drug trial, patients at the NINCDS center will have the opportunity to be included in the Institute’s ongoing research projects on multiple sclerosis.

Physicians who wish to refer patients should contact: Dr. Henry McFarland, NINCDS, Neuroimmunology Branch, Bldg. 10, Rm. 5B18; telephone: (301) 496-1801.

Nominations for Hazen Prize For Clinical Research Open

Nomination material is now available for The 1986 Lita Annenberg Hazen Awards for Excellence in Clinical Research.

Purpose of the awards is to encourage increased participation in clinical research by physician-investigators or teams.

Prizes totalling $100,000 are awarded: $50,000 (tax free) to an outstanding physician-investigator and $50,000 for the support of a research fellow(s).

Nominations will be accepted until Feb. 28, 1986. Candidates of international stature are sought. The 18-member awards committee invites nominations identifying a physician, or a team of physicians jointly conducting research, working at any institution in the world, whose achievements and potential for future breakthroughs in clinical research are outstanding.

Past recipients of the awards include: Jesse Roth, M.D., National Institute of Arthritis, Digestive and Kidney Diseases, 1979; Henry G. Kunkel, M.D., The Rockefeller University, 1980; Aaron B. Lerner, M.D., Yale University School of Medicine, 1981; Michael S. Brown, M.D., and Joseph L. Goldstein, M.D. of the University of Texas Southwestern Medical School, 1982.

An official nomination form plus details on how to submit a nomination are available from Dr. James F. Glenn, President, the Mount Sinai Medical Center; Chairman, The Lita Annenberg Hazen Awards Program; One Gustave L. Levy Place, N.Y., New York 10029 or call (212) 650-8832.